Canopy Growth
Market Cap
CA$9.2b
Last Updated
2019/10/22 00:18 UTC
Data Sources
Company Financials +
Executive Summary
Canopy Growth Corporation, together with its subsidiaries, engages in engages in production, distribution, and sale of cannabis in Canada.
Snowflake
Fundamentals
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Canopy Growth's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0.2%
WEED
-1.3%
CA Pharmaceuticals
0.2%
CA Market
1 Year Return
-50.5%
WEED
-49.1%
CA Pharmaceuticals
2.4%
CA Market
Return vs Industry: WEED matched the Canadian Pharmaceuticals industry which returned -49.1% over the past year.
Return vs Market: WEED underperformed the Canadian Market which returned 2.4% over the past year.
Shareholder returns
| WEED | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.2% | -1.3% | 0.2% |
| 30 Day | -20.9% | -21.1% | -3.3% |
| 90 Day | -42.9% | -32.6% | -1.8% |
| 1 Year | -50.5%-50.5% | -49.1%-49.1% | 6.0%2.4% |
| 3 Year | 349.6%349.6% | 86.3%84.9% | 14.2%4.0% |
| 5 Year | 1336.2%1336.2% | 288.2%288.2% | 27.2%8.6% |
Price Volatility Vs. Market
How volatile is Canopy Growth's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Can We See Significant Institutional Ownership On The Canopy Growth Corporation (TSE:WEED) Share Register?1 month ago | Simply Wall St
Introducing Canopy Growth (TSE:WEED), The Stock That Rocketed 1169% In The Last Five Years2 months ago | Simply Wall St
Is Canopy Growth (TSE:WEED) Using Debt Sensibly?Valuation
Is Canopy Growth undervalued compared to its fair value and its price relative to the market?
1.61x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate WEED's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate WEED's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: WEED is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: WEED is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate WEED's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: WEED is good value based on its PB Ratio (1.6x) compared to the CA Pharmaceuticals industry average (1.8x).
Next Steps
Future Growth
How is Canopy Growth forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?
98.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WEED is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: WEED is forecast to become profitable over the next 3 year, which is considered above average market growth.
High Growth Earnings: WEED's loss is forecast to worsen by 0% next year.
Revenue vs Market: WEED's revenue (53.2% per year) is forecast to grow faster than the Canadian market (5.5% per year).
High Growth Revenue: WEED's revenue (53.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if WEED's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Canopy Growth performed over the past 5 years?
-98.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: WEED is unprofitable, and losses have increased over the past 5 years at a rate of -98.3% per year.
Accelerating Growth: Unable to compare WEED's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WEED is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).
Return on Equity
High ROE: WEED has a negative Return on Equity (-31.57%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: WEED is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: WEED is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Canopy Growth's financial position?
Financial Position Analysis
Short Term Liabilities: WEED's short term assets (CA$3.9B) exceeds its short term liabilities (CA$372.8M)
Long Term Liabilities: WEED's short term assets (3.9B) exceeds its long term liabilities (2.4B)
Debt to Equity History and Analysis
Debt Level: WEED's debt to equity ratio (35.3%) is considered satisfactory
Reducing Debt: WEED's debt to equity ratio has increased from 0.08% to 35.3% over the past 5 years.
Balance Sheet
Inventory Level: WEED has a high level of physical assets or inventory.
Debt Coverage by Assets: WEED's debt is covered by short term assets (assets are 1.857170x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: WEED has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if WEED has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Canopy Growth's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate WEED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate WEED's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if WEED's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WEED's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of WEED's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
What is the CEO of Canopy Growth's salary, the management and board of directors tenure and is there insider trading?
0.3yrs
Average management tenure
CEO
Mark Anthony Zekulin 0
0.3yrs
Tenure
CA$5,958,440
Compensation
Mr. Mark Anthony Nicholas Zekulin has been Chief Executive Officer of Canopy Growth Corporation since July 2, 2019 and has been its Director since July 15, 2019. Mr. Zekulin served as the President at Cano ...
CEO Compensation Analysis
Compensation vs. Market: Mark Anthony has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Canadian market.
Compensation vs Earnings: Mark Anthony's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
0.3yrs
Average Tenure
Experienced Management: WEED's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Age and Tenure
0.9yrs
Average Tenure
59.5yo
Average Age
Experienced Board: WEED's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 3,600 |
| Max Price | CA$52.10 |
| Entity | Individual |
| Role | Chief Executive Officer CEO & Director |
| Shares | 95,374 |
| Max Price | CA$51.41 |
| Entity | Individual |
| Shares | 252 |
| Max Price | CA$42.82 |
| Entity | Individual |
| Shares | 3,600 |
| Max Price | CA$41.99 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 5 |
| Max Price | CA$29.85 |
Ownership Breakdown
Management Team
Chris Schnarr (52yo)
Senior Vice President
- Tenure: 0.08yrs
- Compensation: CA$7.37m
phil Shaer
Chief Legal Officer & VP of Human Resources
- Tenure: 0yrs
- Compensation: CA$2.41m
Tyler Burns
Investor Relations Officer
- Tenure: 0yrs
Mark Anthony Zekulin
CEO & Director
- Tenure: 0.3yrs
- Compensation: CA$5.96m
Rade Kovacevic
Acting President
- Tenure: 0.3yrs
- Compensation: CA$2.52m
Tim Saunders
Strategic Advisor
- Tenure: 0.3yrs
- Compensation: CA$5.93m
Tom Shipley
Senior VP of Global Quality Assurance & Chief Science Officer
- Tenure: 0yrs
Peter Popplewell
Chief Technology Officer
- Tenure: 1.8yrs
Mike Lee
Chief Financial Officer
- Tenure: 0.3yrs
Andre Fernandez
Chief Operating Officer
- Tenure: 0.3yrs
Board Members
Peter Stringham (69yo)
Director
- Tenure: 3.1yrs
- Compensation: CA$321.65k
Bill Newlands (60yo)
Director
- Tenure: 0.9yrs
Robert Hanson (56yo)
Director
- Tenure: 0.9yrs
- Compensation: CA$216.68k
John Bell (72yo)
Lead Director
- Tenure: 0yrs
- Compensation: CA$356.23k
David Klein (55yo)
Chairman of the Board
- Tenure: 0yrs
Judy Schmeling (59yo)
Director
- Tenure: 0.9yrs
- Compensation: CA$225.02k
Mark Anthony Zekulin
CEO & Director
- Tenure: 0.3yrs
- Compensation: CA$5.96m
Company Information
Canopy Growth Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Canopy Growth Corporation
- Ticker: WEED
- Exchange: TSX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$9.243b
- Shares outstanding: 347.87m
- Website: https://www.canopygrowth.com
Number of Employees
Location
- Canopy Growth Corporation
- 1 Hershey Drive
- Smiths Falls
- Ontario
- K7A 0A8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| WEED | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Mar 2014 |
| CGC | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Mar 2014 |
| 11L1 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Mar 2014 |
| 0UO9 | LSE (London Stock Exchange) | Yes | Common Shares | GB | CAD | Mar 2014 |
Biography
Canopy Growth Corporation, together with its subsidiaries, engages in engages in production, distribution, and sale of cannabis in Canada. It operates through two segments, Cannabis Operations and Canopy R ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/22 00:18 |
| End of Day Share Price | 2019/10/21 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.